27 Apr 2023
Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dominic Moreland as its Chief Financial Officer.
Dominic brings with him extensive experience in finance and operations, having held senior leadership roles in several biotech companies previously.
Dominic is a seasoned biopharmaceutical executive with many years experience in the sector and previously served as the finance lead at Autolus Therapeutics through the company’s IPO and NASDAQ listing. He led the MBO and subsequent trade sale of a division of Genzyme Therapeutics UK and prior to that held finance positions with Baxter Healthcare and Zeneca. Dominic is a Chartered Accountant and holds a B.Sc from the London School of Economics.
“We are thrilled to welcome Dominic to the Complement team as CFO,” said Rafiq Hasan, Chief Executive Officer. “Dominic’s experience in financial management will be invaluable as we continue to grow the organisation and develop our pipeline. He played a critical role in the recent successful Series A funding round and we are excited to have him on board to help transform the treatment landscape for complement-mediated diseases.”
“Joining Complement Therapeutics at this stage in the company’s development is a truly exciting opportunity. I believe the team has the potential to make a real difference in the lives of patients with complement-mediate diseases, and I am delighted to be part of it. I look forward to working with the great team we have assembled and building a strong financial foundation for the company as we progress to the clinic.” said Dominic Moreland.